Ampio Pharmaceuticals Inc. (AMEX:AMPE)

Home >> Stock >> Ampio Pharmaceuticals Inc. >> Metrics

Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc, an oral drug for the treatment of diabetic nephropathy. Ampio Pharmaceuticals, Inc. is based in Greenwood Village, Colorado....

+See More
See More

Blog+More

President Trump now agrees to cease fire in the trade conflict with the European Union.

Laura Hermes

2018-07-23 07:41:00 Monday ET

President Trump now agrees to cease fire in the trade conflict with the European Union.

President Trump now agrees to cease fire in the trade conflict with the European Union. Both sides can work together towards *zero tariffs, zero non-tariff

+See More

Japanese prime minister Shinzo Abe outlines the main economic priorities for the G20 summit in Osaka, Japan.

Laura Hermes

2019-07-13 07:17:00 Saturday ET

Japanese prime minister Shinzo Abe outlines the main economic priorities for the G20 summit in Osaka, Japan.

Japanese prime minister Shinzo Abe outlines the main economic priorities for the G20 summit in Osaka, Japan. First, Asian countries need to forge the key Re

+See More

Basic income reforms can contribute to better health care, infrastructure, education, technology, and residential protection.

Daisy Harvey

2023-02-28 10:27:00 Tuesday ET

Basic income reforms can contribute to better health care, infrastructure, education, technology, and residential protection.

Basic income reforms can contribute to better health care, public infrastructure, education, technology, and residential protection. Philippe Van Parijs

+See More

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most corporations.

Daisy Harvey

2023-07-28 11:28:00 Friday ET

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most corporations.

Lucian Bebchuk and Jesse Fried critique that executive pay often cannot help explain the stock return and operational performance of most U.S. public corpor

+See More

The SEC sues Elon Musk for his August 2018 tweet that he has secured external finance to convert Tesla into a private company.

Amy Hamilton

2018-09-29 12:39:00 Saturday ET

The SEC sues Elon Musk for his August 2018 tweet that he has secured external finance to convert Tesla into a private company.

The Securities and Exchange Commission (S.E.C.) sues Elon Musk for his August 2018 tweet that he has secured external finance to convert Tesla into a privat

+See More

The U.S. stock market delivers a hefty long-term average return of 11% per annum.

Peter Prince

2017-03-09 05:32:00 Thursday ET

The U.S. stock market delivers a hefty long-term average return of 11% per annum.

From 1927 to 2017, the U.S. stock market has delivered a hefty average return of about 11% per annum. The U.S. average stock market return is high in stark

+See More